When do Enjaymo (mirvetuximab soravtansine) patents expire?
Enjaymo is a brand name for mirvetuximab soravtansine, but the provided information does not include any patent numbers, filing dates, or jurisdiction-specific details needed to state an expiration date. Patent expiry also depends on factors like whether patents were granted, how long terms were extended, and which country’s patent estate you mean.
Does “patent expiry” mean the same thing as market exclusivity?
No. Even after a patent term ends, regulators can still provide other forms of exclusivity (such as data exclusivity or marketing exclusivity) that affect when competitors can launch. The exact timing requires the relevant regulatory filings and the country/region (for example, US vs. EU).
What do you need to determine Enjaymo’s exact patent expiration date?
To calculate Enjaymo’s patent expiry, you’d typically need:
- The exact active ingredient and formulation match for the Enjaymo product in your country
- The patent family (published application and issued patents) linked to Enjaymo
- The jurisdiction (US, EU/EP, UK, etc.)
- Whether any pediatric extensions or other term adjustments apply
- Whether there are “evergreen” patents (new formulations, new indications, manufacturing changes) that extend coverage
Next best step: share the location and formulation
If you tell me the country/region (for example, United States or European Union/UK) and which Enjaymo product label you mean, I can narrow down the correct patents and explain the expected expiration window—otherwise the precise expiry date can’t be determined from the information provided.
Sources
No sources were provided in the prompt.